Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Larkspur Health Acquisition Corp Cl A (LSPR)

Larkspur Health Acquisition Corp Cl A (LSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 225,653
  • Shares Outstanding, K 10,029
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade LSPR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.25 +143.24%
on 12/09/22
25.00 -10.00%
on 12/12/22
+12.41 (+122.99%)
since 11/10/22
3-Month
9.25 +143.24%
on 12/09/22
25.00 -10.00%
on 12/12/22
+12.50 (+125.00%)
since 09/09/22

Most Recent Stories

More News
ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA")

/PRNewswire/ -- ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to...

LSPR : 22.50 (+132.20%)
ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit

Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to share information and address knowledge gaps...

LSPR : 22.50 (+132.20%)
SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc.

Special meeting of Larkspur stockholders scheduled for December 8, 2022, to vote on the proposed business combination of Larkspur with ZyVersa ZyVersa is a...

LSPR : 22.50 (+132.20%)
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference

Mr. Glover will be joining four other life science executives in a General Session titled, CEO Panel: Learn from the experts ZyVersa is a clinical stage...

LSPR : 22.50 (+132.20%)
ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update

Aggregate committed financing in support of the business combination now at $10.0 million ZyVersa and Larkspur entered into a definitive business combination...

LSPR : 22.50 (+132.20%)
Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging

Age-related chronic inflammation induced by activation of NLRP1 inflammasomes is implicated in development and progression of neurodegenerative diseases such...

LSPR : 22.50 (+132.20%)
Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics

/PRNewswire/ -- Larkspur Health Acquisition Corp. (NASDAQ: LSPR or "Larkspur"), a blank-check special purpose acquisition company, and ZyVersa Therapeutics,...

LSPR : 22.50 (+132.20%)
ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper

/PRNewswire/ -- ZyVersa Therapeutics, Inc., (ZyVersa) a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of...

LSPR : 22.50 (+132.20%)
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar